Objective: We report a new case of Sertoli cell testicular tumor with malignant characteristics.

Methods: 77 year-old male patient, suffering a general wasting syndrome presenting with a left solid testicular mass with the diagnosis of malignant Sertoli cell tumor after orchyectomy, without local, regional or distant dissemination, and a benign outcome after 18 months of follow-up.

Results: Sertoli cell tumor or androblastoma is classified as non-germ cell tumor derived from the stroma of the sexual cords. There are three types depending on its cellular composition: calcified big cell, sclerotic cell, and the most frequent of all, the classic type.

Conclusions: Being the Sertoli cell testicular tumor rare, its malignant type is even rarer, accounting for not more than 10% of all. Despite the pathological characteristics related to malignancy, its posterior behaviour is unpredictable and not much known, the some than follow-up and treatment, because it is not sensible to cytostatic drugs. The existence of metastases continues to be the only valid parameter with prognostic value.

Download full-text PDF

Source
http://dx.doi.org/10.4321/s0004-06142008000700014DOI Listing

Publication Analysis

Top Keywords

sertoli cell
16
cell tumor
12
cell testicular
8
testicular tumor
8
cell
7
tumor
5
[sertoli cell
4
malignant
4
cell malignant
4
malignant tumor]
4

Similar Publications

Hormonal Regulation of Urokinase- and Tissue-Type Plasminogen Activator in Mouse Sertoli Cells.

Mol Reprod Dev

January 2025

Department of Anatomy, Histology, Forensic Medicine and Orthopedic, Section of Histology, Sapienza University of Rome, Rome, Italy.

A role for the plasminogen activator (PA) system has been postulated in mammalian gonads, considering the complex process of morphogenesis these organs undergo during their development. Our results show that mouse Sertoli cells under basal conditions produce both types of PA, tissue-type PA (tPA) and urokinase-type PA (uPA), and hormonal treatments increase the production of both enzymes. The increased enzyme secretion does not correlate with a parallel increase in their mRNAs.

View Article and Find Full Text PDF

The action of retinoic acid on spermatogonia in the testis.

Curr Top Dev Biol

January 2025

School of Molecular Biosciences, Washington State University, Pullman, Washington, United States. Electronic address:

For mammalian spermatogenesis to proceed normally, it is essential that the population of testicular progenitor cells, A undifferentiated spermatogonia (A), undergoes differentiation during the A to A1 transition that occurs at the onset of spermatogenesis. The commitment of the A population to differentiation and leaving a quiescent, stem-like state gives rise to all the spermatozoa produced across the lifespan of an individual, and ultimately determines male fertility. The action of all-trans retinoic acid (atRA) on the A population is the determining factor that induces this change.

View Article and Find Full Text PDF

Background: During mammalian spermatogenesis, the cytoskeleton system plays a significant role in morphological changes. Male infertility such as non-obstructive azoospermia (NOA) might be explained by studies of the cytoskeletal system during spermatogenesis.

Methods: The cytoskeleton, scaffold, and actin-binding genes were analyzed by microarray and bioinformatics (771 spermatogenic cellsgenes and 774 Sertoli cell genes).

View Article and Find Full Text PDF

Transferrin Receptor 2 (TfR2) is a homolog of Transferrin Receptor 1 (TfR1), involved in regulating intra and extracellular iron levels. Altered iron pathways have been associated with cancer onset and progression; however, their role in canine tumors remains poorly explored. This study investigated TfR2 immunohistochemical expression in non-neoplastic canine testis for the first time and in the most common types of canine testicular tumors: intratubular seminomas (ITSEMs), diffuse seminomas (DSEMs), Leydig cell tumors (LCTs), and Sertoli cell tumors (SCTs).

View Article and Find Full Text PDF

Background: Transgender and gender diverse (TGD) people seek gender-affirming care at any age to manage gender identities or expressions that differ from their birth gender. Gender-affirming hormone treatment (GAHT) and gender-affirming surgery may alter reproductive function and/or anatomy, limiting future reproductive options to varying degrees, if individuals desire to either give birth or become a biological parent.

Objective And Rationale: TGD people increasingly pursue help for their reproductive questions, including fertility, fertility preservation, active desire for children, and future options.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!